Therapies for Treatment-Resistant Depression. Neuropharmacology and Neurostimulation

Authors

James Murrough Professor of Psychiatry and Neuroscience, Vice Chair for Clinical Research in Psychiatry, and Director of the Depression and Anxiety Center for Discovery and Treatment, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA. I am Professor of Psychiatry and Neuroscience, Vice Chair for Clinical Research in Psychiatry, and Director of the Depression and Anxiety Center for Discovery and Treatment (DAC) at the Icahn School of Medicine at Mount Sinai (ISMMS). My program of research utilizes molecular, neuroimaging, and experimental therapeutics approaches aimed at elucidating the fundamental mechanisms underlying stress-related disorders in humans, including major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and anxiety disorders. The overall goal of my research is to advance the treatment of stress-related disorders through an enhanced understanding of disease pathogenesis and therapeutic mechanisms of action. Dennis Charney The Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.